Ashish Bansal
YOU?
Author Swipe
View article: Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials
Efficacy and Safety of Dupilumab in Adults with Prurigo Nodularis with or Without Atopic Comorbidities: A Subgroup Analysis from Two Randomized Phase III Clinical Trials Open
ClinicalTrials.gov Identifiers: NCT04183335 and NCT04202679.
View article: Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study
Long-term efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: Results from a phase 3 open-label extension study Open
This analysis supports the long-term efficacy and safety of dupilumab in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis.
View article: The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults
The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults Open
In the most comprehensive dupilumab safety assessment to date, safety was consistent with the known dupilumab safety profile. [Graphical abstract and video abstract available.] TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT0334643…
View article: Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial Open
Sanofi and Regeneron Pharmaceuticals.
View article: Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS
Dupilumab Improves Health-Related Quality of Life and Respiratory Symptoms in Patients With COPD and Type 2 Inflammation: BOREAS and NOTUS Open
gov.
View article: Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis
Immunogenicity of dupilumab in adult and pediatric patients with atopic dermatitis Open
Background Development of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) to monoclonal antibodies may adversely impact pharmacokinetics, efficacy, and/or safety. Objective To describe incidence, titer, and persistence of du…
View article: Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)
Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS) Open
Dupilumab efficacy was similar in patients with COPD and type 2 inflammation, with or without investigator-reported emphysema.
View article: The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study
The effect of dupilumab on caregiver- and patient-reported outcomes in young children with moderate-to-severe atopic dermatitis: Results from a placebo-controlled, phase 3 study Open
Dupilumab improved AD symptoms and QoL in patients and their caregivers/families.
View article: Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years
Dupilumab treatment reduces caregiver-reported skin pain in patients with moderate-to-severe atopic dermatitis aged 6 months to 5 years Open
Background Moderate-to-severe atopic dermatitis (AD) often has a profound impact on the quality of life of young children and their caregivers. One of the most burdensome symptoms reported by patients is skin pain. Methods This post hoc an…
View article: Duplication of Gallbladder Amidst Out of the Ordinary Associated Anomalies
Duplication of Gallbladder Amidst Out of the Ordinary Associated Anomalies Open
Dear Editor, we present a case of a duplicated gallbladder (GB) with exceptionally rare associated anomalies, along with the existing literature about this variant, its anatomical categorization, and surgical implications. There are numero…
View article: Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis
Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis Open
Dear Editor,\nSkin pain and sleep disturbances are key symptoms of atopic dermatitis (AD) that profoundly impact patient quality of life.1, 2 Although skin pain and sleep numeric rating scales (NRS) have been validated for adolescents/adul…
View article: Worst Itch Numeric Rating Scale for Prurigo Nodularis
Worst Itch Numeric Rating Scale for Prurigo Nodularis Open
Importance Prurigo nodularis (PN) is a debilitating skin disease characterized by the hallmark symptom of chronic itch; the intensity of itch in PN was assessed using the Worst Itch Numeric Rating Scale (WI-NRS) to evaluate the primary eff…
View article: Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis
Responder analysis using clinically meaningful thresholds: Post hoc analyses from randomized dupilumab clinical trials in patients with prurigo nodularis Open
Background Prurigo nodularis (PN) is an intensely pruritic disease characterized by itchy nodules on the trunk/extremities; it is often accompanied by skin pain and sleep disruption with negative impacts on the quality of life (QoL). The p…
View article: Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study Open
View article: Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study
Efficacy and safety of dupilumab with concomitant topical corticosteroids in Japanese pediatric patients with moderate-to-severe atopic dermatitis: A randomized, double-blind, placebo-controlled phase 3 study Open
Dupilumab showed consistent efficacy and was well tolerated in Japanese patients aged ≥6 months to <18 years with moderate-to-severe atopic dermatitis previously insufficiently controlled with existing therapies.
View article: Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis
Correction to: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis Open
View article: Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)
Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2) Open
Pooled analysis confirmed improvements reported in individual trials and revealed earlier effect onset in itch and skin pain. Dupilumab treatment showed benefits across demographics.
View article: Estimating meaningful change thresholds for Skin Pain‐Numeric Rating Scale, Sleep‐Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis
Estimating meaningful change thresholds for Skin Pain‐Numeric Rating Scale, Sleep‐Numeric Rating Scale and Dermatology Life Quality Index in patients with prurigo nodularis Open
Background Prurigo nodularis (PN) is characterized by intensely itchy nodules/lesions and skin pain, which can have a substantial impact on health‐related quality of life (HRQoL). Treatment benefits on such symptoms and impacts are best as…
View article: A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis
A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis Open
Background and Objective Current regulatory labeling recommends avoiding live vaccine use in dupilumab‐treated patients. Clinical data are not available to support more specific guidance for live or live attenuated vaccines administration …
View article: Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
Dupilumab treatment improves signs, symptoms, quality of life, and work productivity in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial Open
View article: Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review
Dupilumab Treatment in Pediatric Patients Aged 6–11 Years with Severe Atopic Dermatitis Whose Disease Is Not Adequately Controlled: A Review Open
Atopic dermatitis (AD) is the most common inflammatory skin disease in children. Children with severe AD have a multidimensional disease burden characterized by skin lesions, itching, frequent infections, sleep deprivation, and a high rate…
View article: Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis
Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis Open
The trial was registered with ClinicalTrials.gov with ID number NCT03346434, part B.
View article: Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis
Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis Open
Background While the majority of patients with atopic dermatitis (AD) achieve disease control with dupilumab treatment, there is variability in which patients achieve clear disease. The predictors of these responses are currently unclear. …
View article: 106 Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial
106 Dupilumab treatment in patients with atopic hand and foot dermatitis: Results from a phase 3, randomized, double-blind, placebo-controlled trial Open
View article: S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count
S31 Efficacy of dupilumab in chronic obstructive pulmonary disease with type 2 inflammation by baseline blood eosinophil count Open
Rationale Chronic obstructive pulmonary disease (COPD) is characterized by progressive lung function decline and worsening symptoms, accelerated by recurrent exacerbations. Type 2 (T2) inflammation may play a significant role in a subset o…
View article: A retrospective CT based comparative analysis of available screw pathways to determine optimal iliac screw trajectory
A retrospective CT based comparative analysis of available screw pathways to determine optimal iliac screw trajectory Open
Introduction: The lumbo-sacral stabilization using iliac screw is gaining popularity in such cases of long multi segment lumbar constructs. Iliac screws help to achieve strong spinopelvic fixation, augments and protects sacral screw…
View article: Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family
Clinically meaningful change threshold in health‐related quality of life among patients aged 6 months to 5 years with atopic dermatitis and their caregiver(s)/family Open
Background Atopic dermatitis (AD) significantly impacts health‐related quality of life (HRQoL) in children and their caregiver(s)/family. Measures to assess HRQoL include the Children's Dermatology Life Quality Index (CDLQI), Infants' Derm…
View article: Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch/itch in patients aged 6 months to younger than 6 years with atopic dermatitis
Development and validation of a caregiver-reported Numeric Rating Scale for measuring worst scratch/itch in patients aged 6 months to younger than 6 years with atopic dermatitis Open
To the Editor: In patients with atopic dermatitis (AD), reduction of itch is a key therapeutic goal and a marker of treatment benefit.1 Worst Itch Scale is a validated scale for self-evaluation of itch in children aged 6-11 with AD.2 For p…
View article: Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis Open
The above infographic and video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read t…
View article: Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years
Dupilumab Treatment Leads to Rapid and Consistent Improvement of Atopic Dermatitis in All Anatomical Regions in Patients Aged 6 Months to 5 Years Open
ClinicalTrials.gov Identifier: NCT03346434 Part B.